Loading
Lymphoma Diagnosis and Treatment · Review
Frontiers in Veterinary Science · August 12, 2026
Encouraging direction, but not yet definitive.
This meta-analysis aggregated 11 clinical trials testing tyrosine kinase inhibitors in canine lymphoma and found an objective response rate of 42%, with a possible differential effect by cell type (T-cell lymphoma 63% vs. B-cell lymphoma 27%). The finding is consistent with moderate antitumor activity but insufficient to establish standard-of-care efficacy or safety without additional confirmatory work.
Systematic review and meta-analysis of clinical trials. Dogs with lymphoma; studies included both T-cell and B-cell lymphoma subtypes across clinical trials and in vitro experiments. Intervention: Tyrosine kinase inhibitors (TKIs) for treatment of canine lymphoma. n = 101.
Meta-analysis of 101 dogs across 11 clinical trials showed objective response rate (ORR) of 42% (95% CI: 32–53%) Canine T-cell lymphoma exhibited higher response rate (ORR = 0.63) compared to canine B-cell lymphoma (ORR = 0.27) Seventeen articles included: 11 clinical trials and 9 in vitro experiments; some studies encompassed both methodologies
Optimal TKI dosing, administration schedule, and safety profile not systematically compared across studies
These results support further investigation of TKIs in lymphoma but do not yet warrant routine clinical adoption in either veterinary or human practice. Clinicians should view this as evidence for continued research and potential cell-type-directed approaches, while awaiting larger, better-controlled trials with prospective safety monitoring.
Meta-analysis of 11 clinical trials in 101 dogs shows moderate objective response rate (42%) with potential cell-type variation, supporting TKI investigation but requiring confirmation of efficacy, safety, and optimal dosing strategies.
As stated by the source record.
Quoted from the source exactly as published.
These results support further investigation of TKIs in lymphoma but do not yet warrant routine clinical adoption in either veterinary or human practice. Clinicians should view this as evidence for continued research and potential cell-type-directed approaches, while awaiting larger, better-controlled trials with prospective safety monitoring.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
Background Canine lymphoma (cL), the second most common canine cancer after mammary carcinoma, presents therapeutic challenges due to limitations of conventional regimens, necessitating novel therapeutic approaches. Tyrosine kinase inhibitors (TKIs), which have demonstrated efficacy in human non-Hodgkin lymphoma (NHL), are increasingly being investigated as targeted therapies for cL, which also serves as a valuable translational model for NHL research. Objectives To systematically evaluate the efficacy of TKIs in the treatment of cL. Methods A comprehensive search of PubMed, Web of Science, Cochrane, and Embase databases was conducted, encompassing studies published between January 1, 2004 and January 1, 2026, using controlled vocabulary terms including “Canine,” “Dogs,” “Lymphoma,” and “Tyrosine Kinase Inhibitors”. A meta-analysis was subsequently performed to evaluate the efficacy of TKIs. Results Seventeen articles were included, comprising 11 clinical trials and 9 in vitro experiments, with some studies encompassing both methodologies. A meta-analysis encompassing 101 dogs from 11 clinical trials showed an objective response rate (ORR) of 42% (95% CI: 32–53%; common-effect model), indicating moderate antitumor activity. Notably, canine T-cell lymphoma (ORR = 0.63) may exhibit a higher response rate compared to canine B-cell lymphoma (ORR = 0.27). Conclusions TKIs show moderate therapeutic activity in cL and support the role of dogs as a translational model for NHL research. However, further studies are needed to confirm their efficacy and safety and to explore optimal combination and personalized treatment strategies.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.